Swissmedic

Summary report on authorisation – Breyanzi®

Marketing authorisation granted for Breyanzi® (lisocabtagene maraleucel), a chimeric antigen receptor T-cell therapy.

Low obligation Product class Pharmaceuticals Switzerland Pharmaceuticals

22.06.2026

Dates and deadlines

Applies from

2026-06-22

Read the official source ↗

Published by Swissmedic. HealthSignal links to the original document; the summary above is extracted from the source text.